Impact BioMedical Inc. — Form 8-K Summary
Report date: January 18, 2024; filed January 22, 2024. The filing reports entry into a material amendment to the company’s revolving promissory note with DSS, Inc., its majority shareholder. It does not provide operating results for a reporting period.
Material Financing Terms
- DSS originally agreed to provide Impact with up to $12.0 million under a March 1, 2023 revolving promissory note.
- The amendment increased the funded principal balance to $12,859,328.60, including funds advanced to pay accrued interest through the amendment date.
- The revolving advance feature was eliminated.
- The maturity date was extended to September 30, 2030.
- Interest was amended to a floating rate of WSJ Prime plus 0.50%, initially 9.0% per annum.
- After maturity, the interest rate is the lesser of the maximum rate permitted by law or 18.0% per annum, calculated on a 360-day year.
- The obligation is secured by a blanket first lien on all Impact assets, including licenses and patents.
Repayment and Liquidity Implications
- Principal and interest are payable on demand if DSS makes a demand.
- If no demand is made, Impact will pay accrued interest monthly from February 2024 through January 2026.
- From February 2026 through August 2030, Impact will make monthly payments of $126,380.80, consisting of principal and interest.
- All unpaid principal and interest will be due on September 30, 2030.
- Impact may prepay all or part of the obligation without penalty.
- The filing provides no cash balance, revenue, profit, cash-flow, margin, or other operating metrics. The demand feature and security interest represent significant liquidity and asset-pledge considerations.
Changes, Related-Party Matters, and Risks
- Compared with the original note, the amendment extends maturity, increases the funded balance through interest funding, removes further borrowing capacity, establishes repayment terms, and changes the interest rate to a market-based floating rate.
- DSS is Impact’s majority shareholder, making the transaction a related-party financing arrangement.
- Impact agreed to indemnify DSS and certain related parties for losses, liabilities, expenses, and claims connected with the note, loan documents, or related transactions.
- For certain curable defaults, Impact generally has 10 business days after written notice to cure, or must promptly begin and complete reasonable corrective steps if more time is required. The filing does not provide a complete summary of all default provisions.
- The filing contains no business guidance, operating outlook, contingency forecast, or management discussion of future performance.
Key Facts for Investors to Verify
- Confirm the full amendment terms in Exhibit 10.1, including all events of default, remedies, covenants, and collateral provisions.
- Verify the outstanding principal and accrued interest balances in subsequent financial statements.
- Assess Impact’s ability to satisfy possible demand obligations and scheduled payments through 2030.
- Monitor changes in WSJ Prime because the interest rate is floating.
- Evaluate the related-party nature of the financing and the scope of the blanket first lien over Impact’s assets, licenses, and patents.